BG
SGMO

Bollard Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bollard Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,273
Closed -$7K – 392
2022
Q1 		$7K Hold
1,273
– – ﹤0.01% 410
2021
Q4 		$10K Hold
1,273
– – ﹤0.01% 412
2021
Q3 		$11K Hold
1,273
– – ﹤0.01% 406
2021
Q2 		$15K Hold
1,273
– – ﹤0.01% 400
2021
Q1 		$16K Hold
1,273
– – ﹤0.01% 400
2020
Q4 		$20K Hold
1,273
– – ﹤0.01% 388
2020
Q3 		$12K Hold
1,273
– – ﹤0.01% 405
2020
Q2 		$11K Buy
+1,273
New +$11.8K ﹤0.01% 429

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bollard Group's SGMO Position: Q2 2022 in Review

Bollard Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2022, closing a stake of 1,273 shares — an estimated $7K sold.

Bollard Group first reported a position in SGMO in Q2 2020 and held it in 8 quarters. The position peaked at $20K in Q4 2020. 188 funds tracked by Wall St. Rank hold SGMO as of Q2 2022.

  • Bollard Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 1,273 SANGAMO THERAPEUTICS INC shares in Q2 2022, an estimated $7K.
  • Bollard Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2020 and held it in 8 quarters.
  • Bollard Group's SANGAMO THERAPEUTICS INC position peaked at $20K in Q4 2020.
  • 188 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.